of prasugrel alone. Increasing platelet inhibition could increase bleeding risk. The relationship between inhibition of platelet aggregation and clinical activity has not been established. Pharmacokinetics Prasugrel is a prodrug and is rapidly metabolized by carboxylesterase 2 in the intestine and carboxylesterase 1 in the liver to a likewise inactive thiolactone, which is then converted by CYP3A4 and CYP2B6, and to a minor extent by CYP2C9 and CYP2C19, to a pharmacologically active metabolite (R-138727). R-138727 has an elimination half-life of about 7 hours (range 2 h to 15 h). Healthy subjects, patients with stable atherosclerosis, and patients undergoing PCI show similar pharmacokinetics. Chemistry Prasugrel has one chiral atom. It is used in racemic form as the hydrochloride salt, which is a white powder. References Further reading External links claims prasugrel compound; expired on 14 April 2017 claims hydrochloride salt of prasugrel; will expire on 3 July 2021 Adenosine diphosphate receptor inhibitors Eli Lilly and Company brands Daiichi Sankyo Fluoroarenes Ketones Thienopyridines Acetate esters Cyclopropanes